Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Pluri ( (PLUR) ) has issued an update.
Pluri Inc. reported a decrease in total assets from $39.5 million in June 2024 to $30.9 million by December 2024, reflecting financial challenges. The company experienced a net loss of $9.1 million for the six months ending December 2024, driven by high research and administrative expenses. Despite these financial difficulties, Pluri continues its development efforts with participation from international organizations, indicating a focus on long-term growth and stability.
More about Pluri
Pluri Inc. operates in the biotechnology industry, offering advanced technological solutions primarily focused on regenerative medicine. The company is based in Haifa, Israel, and is known for its innovation in cellular therapy and tissue engineering.
YTD Price Performance: -0.69%
Average Trading Volume: 22,728
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $24.74M
See more insights into PLUR stock on TipRanks’ Stock Analysis page.
